{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:46:24Z","timestamp":1762004784249},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/md.0000000000003406","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T12:10:15Z","timestamp":1461240615000},"page":"e3406","source":"Crossref","is-referenced-by-count":10,"title":["Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma"],"prefix":"10.1097","volume":"95","author":[{"given":"Yong","family":"Xin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Qin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210226","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/jid.2008.423","article-title":"Increasing burden of melanoma in the United States","volume":"129","author":"Linos","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R2-21-20210226","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-21-20210226","doi-asserted-by":"crossref","first-page":"986408","DOI":"10.1155\/2013\/986408","article-title":"Cancer mortality among Asians and Pacific Islanders in New York City, 2001-2010","volume":"2013","author":"Huang","year":"2013","journal-title":"J Cancer Epidemiol"},{"key":"R4-21-20210226","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma - a review of current and future treatment options","volume":"95","author":"Maverakis","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R5-21-20210226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-11-38","article-title":"Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-\u03b1 inadvanced malignant melanoma","volume":"11","author":"Daponte","year":"2013","journal-title":"J Transl Med"},{"key":"R6-21-20210226","first-page":"1","article-title":"Inducers and induction of interferon","volume":"2","author":"Torrence","year":"1977","journal-title":"Pharmacol Ther"},{"key":"R7-21-20210226","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-4362.1982.tb00478.x","article-title":"The human interferon system","volume":"21","author":"Berman","year":"1982","journal-title":"Int J Dermatol"},{"key":"R8-21-20210226","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00008390-200102000-00009","article-title":"Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials","volume":"11","author":"Huncharek","year":"2001","journal-title":"Melanoma Res"},{"key":"R9-21-20210226","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy forthe treatment of metastatic melanoma: a meta-analysis of 18trials involving 2,621 patients","volume":"25","author":"Ives","year":"2007","journal-title":"J Clin Oncol"},{"key":"R10-21-20210226","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1479-5876-6-62","article-title":"Adjuvant therapy of melanoma with interferon:lessons of the past decade","volume":"6","author":"Ascierto","year":"2008","journal-title":"J Transl Med"},{"key":"R11-21-20210226","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIb melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J Clin Oncol"},{"key":"R12-21-20210226","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"R13-21-20210226","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-8-76","article-title":"Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment","volume":"8","author":"Ascierto","year":"2010","journal-title":"J Transl Med"},{"key":"R14-21-20210226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/path.4259","article-title":"New drug targets in metastatic melanoma","volume":"232","author":"Homet","year":"2014","journal-title":"J Pathol"},{"key":"R15-21-20210226","doi-asserted-by":"crossref","first-page":"2353s","DOI":"10.1158\/1078-0432.CCR-05-2503","article-title":"Cytokine-based therapy and biochemotherapy for advanced melanoma","volume":"12","author":"Atkins","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R16-21-20210226","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.seminoncol.2009.07.001","article-title":"Melanoma in pediatric, adolescent, and young adult patients","volume":"36","author":"Kirkwood","year":"2009","journal-title":"Semin Oncol"},{"key":"R17-21-20210226","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.1992.10.12.1919","article-title":"A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma","volume":"10","author":"Pyrh\u00f6nen","year":"1992","journal-title":"J Clin Oncol"},{"key":"R18-21-20210226","first-page":"458","article-title":"Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clin Oncol (R Coll Radiol"},{"key":"R20-21-20210226","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01571406","article-title":"Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma","volume":"12","author":"Falkson","year":"1995","journal-title":"Med Oncol"},{"key":"R21-21-20210226","first-page":"s155","article-title":"Advanced malignant melanoma: DTIC plus rIFN-alfa-2b vs DTIC alone","volume":"27","author":"Galvez","year":"1991","journal-title":"Eur J Cancer"},{"key":"R22-21-20210226","first-page":"133","article-title":"Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial","volume":"3","author":"Thomson","year":"1993","journal-title":"Melanoma Res"},{"key":"R23-21-20210226","first-page":"303","article-title":"3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma","volume":"3","author":"Ascierto","year":"1999","journal-title":"Int J Mol Med"},{"key":"R24-21-20210226","first-page":"1183","article-title":"Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study","volume":"77","author":"Avril","year":"1990","journal-title":"Bull Cancer"},{"key":"R25-21-20210226","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clon.2011.12.002","article-title":"Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline","volume":"24","author":"Petrella","year":"2012","journal-title":"Clin Oncol (R Coll Radiol"},{"key":"R26-21-20210226","first-page":"CD008955","article-title":"Interferon alpha for the adjuvant treatment of cutaneous melanoma","volume":"6","author":"Mocellin","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-21-20210226","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","article-title":"Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma","volume":"13","author":"Rozera","year":"2015","journal-title":"J Transl Med"},{"key":"R28-21-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2014.12.050","article-title":"Advances in targeted therapy for unresectable melanoma: new drugs and combinations","volume":"359","author":"Hao","year":"2015","journal-title":"Cancer Lett"},{"key":"R29-21-20210226","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","article-title":"Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study","volume":"16","author":"Falkson","year":"1998","journal-title":"J Clin Oncol"},{"key":"R30-21-20210226","first-page":"93","article-title":"DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma","volume":"43","author":"Rudolf","year":"1995","journal-title":"Neoplasma"},{"key":"R31-21-20210226","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1994.12.4.806","article-title":"Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma","volume":"12","author":"Bajetta","year":"1994","journal-title":"J Clin Oncol"},{"key":"R32-21-20210226","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.1991.9.8.1403","article-title":"Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma","volume":"9","author":"Falkson","year":"1991","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:22:32Z","timestamp":1620958952000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201604190-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003406","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}